Merck oncology VPs Gregory Lubiniecki (L) and Scot Ebbinghaus
September 7, 2022 06:05 PM EDT
R&D

#ES­MO22: Out­side liv­er can­cer, Keytru­da notch­es key win in neoad­ju­vant set­ting but flops in head and neck tu­mors

Paul Schloesser

Associate Editor

ES­MO in Paris is just get­ting start­ed, and ex­clud­ing a promi­nent miss in liv­er can­cer, Mer­ck is kick­ing things off with two ad­di­tion­al swings …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times